Summit Therapeutics Inc. <SMMT.O>: Leerink Partners raises to market perform from underperform; raises target price to $13 from $12
SMMT•Related News
Israel's Radcom Q2 revenue falls 33% on deployment delays
RDCM•
WeRide 2Q FY26 loss narrows 1.4% YoY to RMB 400.7 million; revenue rises 82.2% YoY to RMB 231.7 million
WRD•
American Homes 4 Rent <AMH.N>: Morgan Stanley cuts target price to $38.00 from $38.50
AMH•
Lumentum Holdings Inc. <LITE.O>: BofA Global Research cuts price objective to $1000 from $1100
LITE•
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug
NBIX•